echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Natural Products News > J child adol psychoph: studies have found that dasotriline can treat children's inattention

    J child adol psychoph: studies have found that dasotriline can treat children's inattention

    • Last Update: 2019-03-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    March 17, 2019 / BIOON / - a new study published in Journal of child and adolescent psychology shows that the treatment of 4 mg dasotraline per day can significantly improve the symptoms of 6-12-year-old children with attention-deficit / hyperactivity disorder (ADHD) Photo source: Dr Robert L finding from Johns Hopkins University and colleagues randomly divided 342 children (average 9.1-year-old, 66.7% boys) with ADHD into three groups, who received 2 and 4 mg of dasotroline or placebo daily The researchers found that 4 mg / day of dasotroline was associated with a significant improvement in ADHD symptoms, while 2 mg / day had no significant effect But more children who stopped taking 4 mg / day due to serious side effects than those who stopped taking 2 mg / day (12.2% and 6.3%, respectively, compared with 1.7% in the placebo group) Insomnia, loss of appetite, weight loss and irritability are the most common adverse events related to dasotriline 7 of 219 patients who took dasotriline had symptoms related to mental illness "The results of this study provide valid data for the safety, efficacy and daily dose of dasotriline, indicating that the drug can effectively treat ADHD, with a lower probability of abuse and a longer half-life, so it can be taken every 24 hours." The study authors wrote The authors also announced financial relationships with several pharmaceutical companies, including sunovion, which produced the drug and funded the study Reference: Robert L finding et al Dasotraline in children with attention defense / hyperactivity disorder: a six week, placebo controlled, fixed dose trial Journal of child and adolescent psychopharmacology Doi: https://doi.org/10.1089/cap.2018.0083
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.